Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY:JNJ)

190.72 -0.36 (-0.19%)
Official Closing Price Updated: 7:00 PM EDT, Oct 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
99 100 Next >
Johnson & Johnson Reports Strong Q1 Performance
Johnson & Johnson's first-quarter results surpassed expectations with notable growth in sales and earnings. 
Via Talk Markets
Topics Stocks / Equities
Johnson & Johnson’s (NYSE:JNJ) Q1 Sales Top Estimates, Full-Year Sales Guidance is Optimistic
Multinational healthcare company Johnson & Johnson (NYSE:JNJ) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 2.4% year on year to $21.89 billion. The company’s... 
Via StockStory
Topics Intellectual Property
Johnson & Johnson Announces 63rd Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 4.8%
From Johnson & Johnson
Via Business Wire
Johnson & Johnson Reports Q1 2025 Results
From Johnson & Johnson
Via Business Wire
US Stock Futures Waver After Two-Day Rally: Trump's Tariff Moves Could End A 3-Year 'Rolling Recession,' Says Expert
U.S. stock futures were volatile on Tuesday following a two-day advance. Futures of major benchmark indices were mixed in premarket. 
Via Benzinga
Topics Government
Citigroup, Bank Of America And 3 Stocks To Watch Heading Into Tuesday
 
Via Benzinga
Earnings Scheduled For April 15, 2025
 
Via Benzinga
Johnson & Johnson Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
 
Via Benzinga
US Stock Futures Slip As Investors Brace Themselves For Netflix, AmEx Earnings This Week — Nikkei Up On Strong Sentiment
After two days of back-to-back gains in the spot market, U.S. stock futures had a choppy session Monday night as investors await several prominent companies' earnings reports this week. 
Via Benzinga
34-Year-Old Making $3,400 a Month in Dividends Shares His Top 7 Stocks — 'Be Lucky and Save Relentlessly'
 
Via Benzinga
Johnson & Johnson (JNJ) Reports Earnings Tomorrow: What To Expect
Multinational healthcare company Johnson & Johnson (NYSE:JNJ) will be reporting results tomorrow before market open. Here’s what investors should know. 
Via StockStory
Topics Artificial Intelligence
Examining the Future: Johnson & Johnson's Earnings Outlook
 
Via Benzinga
Are Tariff Worries Affecting The Earnings Outlook?
There are valid reasons for the market to remain focused on the tariffs issue since so much is happening in the broader economy. 
Via Talk Markets
Topics Stocks / Equities World Trade
Novartis Commits $23 Billion To Expand US Manufacturing Over Five Years, Despite Tariffs Uncertainties
Novartis commits $23 billion to expand U.S. manufacturing and R&D with 10 new facilities, aiming to produce all key U.S. medicines domestically and add thousands of jobs. 
Via Benzinga
Eli Lilly, AbbVie, Bristol Myers, Regeneron, And Other Pharma Companies Slide As Donald Trump Confirms Tariffs On Pharma Companies
Even as Donald Trump paused the reciprocal tariffs for 90 days, he later confirmed that pharmaceutical companies would face tariffs. 
Via Benzinga
Topics Government World Trade
2 Top Dividend Stocks to Buy Right Now
Via The Motley Fool
Topics Artificial Intelligence Government Lawsuit
S&P, Dow Jones Pharma Names Rattled — Again — On Trump's Tariffs Whiplash
Here's why the 90-day tariffs delay doesn't help pharmaceutical companies. 
Via Investor's Business Daily
Topics Government Stocks World Trade
Johnson & Johnson, Protagonist Tout Positive Results For Psoriasis Oral Pill Study
Protagonist and Johnson & Johnson report positive Phase 3 data on icotrokinra in adolescent plaque psoriasis, showing high clearance rates and favorable safety. 
Via Benzinga
Alphabet To $185? Here Are 10 Top Analyst Forecasts For Thursday
 
Via Benzinga
If Your Portfolio Is Down on the Tariff News, Check Out This Little-Known High-Yield Dividend Stock
Investors are dumping growth stocks right now as new tariff policies rock the markets. 
Via The Motley Fool
Topics Artificial Intelligence Economy Government
Stock Market Sell-Off Shopping Spree: 3 Top Dividend Stocks I Just Bought to Boost My Passive Income
Via The Motley Fool
Topics Bonds
The Dow Crashed 4,260 Points in 3 Days: Here Are 3 Dow Stocks That Make for No-Brainer Buys Right Now
Three of the Dow's 30 components make for sensational buys amid a historic sell-off. 
Via The Motley Fool
Topics Credit Cards Economy Stocks
This Johnson & Johnson Analyst Turns Bullish On Shifting Focus From Stelara Concerns To Innovative Medicine
Goldman Sachs upgraded Johnson & Johnson (JNJ) from Neutral to Buy, citing underappreciated Innovative Medicine business and upcoming product cycles. 
Via Benzinga
Tesla Underdelivers
And we take a look at Texas Instruments and Taiwan Semiconductor. 
Via The Motley Fool
Topics Government World Trade
Dow Jones, S&P 500 Pharma Names Slammed As New Trump Tariffs Target Drug Imports
Big pharmaceutical names plowed lower Wednesday after Trump on Tuesday said that tariffs would take aim at drug imports. 
Via Investor's Business Daily
Topics Government Stocks World Trade
Amazon.com To $255? Here Are 10 Top Analyst Forecasts For Wednesday
 
Via Benzinga
This Apple Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday
 
Via Benzinga
Cell Therapy Maker Legend Biotech Is An 'Attractive Opportunity' Due To No Material Tariff Exposure: Analyst
Legend Biotech's Carvykti shows strong efficacy in multiple myeloma as U.S.-based manufacturing shields it from tariffs and global regulatory risks. 
Via Benzinga
Topics World Trade
As Trump Tariffs Spark Panic, Investors Rush Into These 5 'Recession-Proof' ETFs
ETFs that provide exposure to sectors that have historically been considered defensive during downturns are now in the limelight. 
Via Benzinga
Topics ETFs Government
Johnson & Johnson's New 'Compelling Data' Shows Sustained Symptom Improvement In Muscular Disease Patients
Johnson & Johnson reports long-term efficacy and steroid-sparing benefits of nipocalimab in antibody-positive generalized myasthenia gravis. 
Via Benzinga
< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.